Strong TAVR sales help Edwards Lifesciences increase revenue in first quarter

Led by a 37 percent increase in its transcatheter heart valve sales, Edwards Lifesciences reported on April 26 that its revenue increased 18.1 percent and its earnings per share increased 17.9 percent during the first quarter of 2016.

The company announced it had $367.8 million in sales in the transcatheter heart valve therapy division, including $216.4 million in the U.S., a 64.1 percent increase from the first quarter of 2015.

In June, the FDA approved the third-generation Sapien 3 transcatheter aortic valve replacement (TAVR) system from Edwards to treat high-risk patients with severe aortic stenosis. The FDA previously approved the Sapien and Sapien XT devices.

The transcatheter heart valve therapy division accounted for more than half of Edwards’ $697.3 million in quarterly sales. For the first quarter, U.S. and international sales for the company were $375.6 million and $321.7 million, respectively.

Sales decreased 0.5 percent to $195.9 million in the surgical heart valve therapy division and increased 7.0 percent to $133.6 million in the critical care division.

During the quarter, Edwards generated $107.1 million in cash flow from operating activities and had a free cash flow of $79.4 million. In addition, its GAAP earnings per share increased 17.9 percent to $0.66 per share.

For 2016, Edwards raised its sales guidance to $2.7 billion to $3.0 billion, up from $2.6 billion to $2.85 billion. The company also increased its adjusted earnings per share guidance to $2.67 to $2.77 per share.

“Our strong start to 2016 positions us well for another successful year,” Edwards CEO Michael A. Mussallem said in a news release. “We are enthusiastic about the continued expansion of transcatheter-based therapies for the many structural heart patients still in need. We are confident in our outlook for strong sales growth, and we remain passionate about developing impactful therapies to help more patients around the world.”

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."